For research and educational purposes only. Not medical advice.
PNC-27 Reference
Educational, not medical advice reference for PNC-27: Immune; regulatory status, evidence posture, source review, and schedule notes. Also known as p53-deriv…
Reference summary
In-vitro and mechanistic studies describe cancer-cell membrane HDM-2 binding, pore formation, and mitochondrial disruption. Human clinical efficacy data are absent.
- Categories
- Immune
- Aliases
- p53-derived HDM-2-binding peptide, PNC27, Anticancer research peptide
- Evidence posture
- preclinical — Fringe anticancer peptide. No human clinical efficacy evidence; using it instead of oncology care would be medically dangerous. This entry is educational source indexing only.
- Regulatory status
- No FDA-approved PNC-27 drug label. PNC-27 is not an approved cancer treatment. Published work is mostly cell, mechanistic, and preclinical oncology research.
- Content review status
- research reference